Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA
vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to …

B-cell maturation antigen (BCMA) was originally identified as a cell membrane receptor,
expressed exclusively on late stage B-cells and plasma cells (PCs). Investigations of BCMA …

Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk
stratification to avoid under-and overtreatment. We hypothesized that replacing bone …

Abstract Purpose: Reduced uninvolved immunoglobulin (Ig) levels are a hallmark of multiple
myeloma. We previously showed that B-cell maturation antigen (BCMA) is solubilized and at …

We measured immunosuppression at myeloma diagnosis and assessed the impact on
survival in 5826 UK myeloma trial patients. Polyclonal immunoglobulin levels were below …

Monoclonal gammopathies (MG) are characterized by the proliferation of plasma cells that
produce identical abnormal immunoglobulins (intact or some of their subunits). This …

Simple Summary We investigated the influence of autophagy-related variants in modulating
Multiple Myeloma (MM) risk through a meta-analysis of germline genetic data on 234 …

Immunoparesis (hypogammaglobulinemia) is associated to an unfavorable prognosis in
newly diagnosed Multiple myeloma (MM) patients. However, this finding has not been …

Objectives Infections pose the greatest risk of early death in patients with Multiple Myeloma.
However, few studies have analyzed the risk factors for infections in Multiple Myeloma …